Business Segments · Goodwill, related to acquisitions
Innovative Medicine — Goodwill, related to acquisitions
Johnson & Johnson Innovative Medicine — Goodwill, related to acquisitions decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2011
Last reportedQ1 2026Apr 22, 2026
Rolls up toGoodwill Additions
How to read this metric
Higher values indicate aggressive inorganic growth and investment in future pipeline expansion.
Detailed definition
Captures the specific portion of goodwill added to the Innovative Medicine segment balance sheet resulting from inorgani...
Peer comparison
Comparable to 'Acquisition-related Goodwill' in segment disclosures for life sciences peers.
Metric ID:
jnj_segment_innovative_medicine_goodwill_related_to_acquisitionsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $290.00M | $273.00M | $57.00M | $20.00M | $0.00 | $2.88B | $0.00 | $642.00M | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | -5.9% | -79.1% | -64.9% | -100.0% | — | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | +953.5% | -100.0% | >999% | — |
Range$0.00 – $2.88B
Avg YoY Growth+965.9%
Median YoY Growth+426.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — goodwill, related to acquisitions?
- Johnson & Johnson (JNJ) reported innovative medicine — goodwill, related to acquisitions of $0.00 in Q1 2026.
- What does innovative medicine — goodwill, related to acquisitions mean?
- The amount of goodwill added to the Innovative Medicine segment due to new acquisitions.